Net loss was reduced the existing fiscal quarter primarily because of the receipt of a $0.2 million non-taxable grant beneath the Qualifying Therapeutics Discovery Project program and $0.3 million of lower spending resulting from continuing cost containment activities undertaken by the Firm. These reductions to the present quarter loss were partially offset by a $0.2 million increase in reduction from discontinued operations. Net loss for the fiscal calendar year 2010 was $7.3 million, or $0.19 per share, compared with a net loss of $10.0 million, or $0.31 per share, for 2009.Related StoriesAstellas enters into definitive contract to acquire OcataFirst individual of U.S. This lack of clinical data helps it be difficult to judge the efficacy of these therapies. New therapies developed for regional and global health issues The study discovered that the government’s focus on innovation can be driving development of brand-new therapies to handle significant local health needs, including lung fibrosis, liver cirrhosis and various problems connected with an aging populace caused partly by the country’s one-child policy. Lung fibrosis, due to radiation treatment, is usually a major reason behind death for the a lot more than 275,000 Chinese who die from lung cancer every full year.